BIA update - 14 August 2023

A summer of consultations.

Politicians may have packed their bags for the parliamentary recess, but they leave behind a number of open consultations to which the BIA and our members will be responding over the summer, with all the energy of a Taylor Swift-themed SoulCycle class in LA. Responding to consultations is one of the ways in which we help shape public policy supported by our ongoing engagement across government.

Following the BIA’s long-running and successful campaign on tax reliefs for R&D which culminated in the positive announcements in the Spring Budget, the Government has published draft legislation and a policy paper setting out the proposed design of a new merged R&D tax relief regime and enhanced rate for R&D intensive SMEs. It welcomes comments on the technical detail of the draft legislation as part of the technical consultation process for the draft Finance Bill. The deadline is 12 September. The BIA is responding and if you would like to feed into the consultation directly, please email [email protected]. It would be great to hear your views, please contact [email protected] to let us know how you have responded.

Another consultation relevant to our campaign to increase access to finance for innovative biotech (an effort headed up by the Government’s life science investment envoy and BIA chair, Dan Mahony) is a call for evidence on pension trustee culture, which seeks to understand trustee skills and capability, barriers to trustee effectiveness, including fiduciary duty, and the role of advisers, including investment consultants. The objective and BIA’s interest in the consultation is to raise awareness and understanding of our sector as an investment opportunity in the pensions industry and also remove the over-reliance on fees as a marker of value for money, which is a barrier to venture investment. Another consultation we’ll be looking at seeks views on the accelerated consolidation of local government pension schemes so that they can reach the scale needed to invest in venture capital.

There has been an increased focus on antimicrobial resistance (AMR) recently. Following the success of the pilot project for a subscription model for antimicrobials, NHS England and NICE have launched a consultation on their proposals to expand that approach to more antimicrobial products. The proposals aim to incentivise greater investment into R&D for antimicrobials, by providing companies with a fixed annual fee of up to £20 million, based primarily on the value of the drug to the NHS, as opposed to the volumes used. The consultation is open until 2 October, and the BIA will be developing its response with input from members working in the AMR space.

Engineering Biology is a vibrant and growing part of biotech, so the Department for Science, Innovation and Technology (DSIT) call for evidence on engineering biology is particularly welcome. This consultation asks for experiences and insights into the strengths, weakness and opportunities for the UK’s engineering biology ecosystem. This includes the regulatory environment and standards, business ecosystem, talent and skills, the knowledge pipeline, the UK value and supply chain, public understanding and uptake of engineering biology products, as well as future expectations.

The outcomes of this call for evidence will inform government policy that will support the engineering biology ecosystem. BIA members active in synthetic or engineering biology are encouraged to actively engage with this call for evidence, as it will be the basis for a multi-year government action plan on engineering biology. BIA’s Policy and Public Affairs Manager, Linda Bedenik, is preparing a response in close consultation with BIA’s Engineering Biology Advisory Committee (EBAC) and wider member input. Please do get in touch to share your views and shape the BIA’s response, or respond to the call for evidence directly. The deadline for submissions is 29 September 2023.

The BIA and its members have a great track record of bringing high quality evidence to the policy making process through consultations that we know is influential and welcomed by policy makers. 


Nicky Edwards

Nicky Edwards

Director of External Affairs

More news and updates 

CEO Update - 10 June 2024

UK General Election and what it might mean for the industry, including Labour's pledges on Brexit and business taxes. Upcoming events including the Cambridge Wide Open Day and the Life Science Leadership Summit. UK tech companies pitching at the London Stock Exchange and Amber Therapeutics securing $100 million in funding.

Women in Biotech Mentoring Programme: Dr Carolina Grandellis

In this interview, Dr Carolina Grandellis, Lead of the Earlham Institute Biofoundry, explores the profound impact of the BIA's Women in Biotech mentoring programme on her professional and personal life.

An urgent call for technical standards and metrics for engineering biology

There are currently very few technical standards and metrics that are specific and appropriate to the field of engineering biology. Across the innovation pipeline, there are opportunities for standards to support faster development and enable accelerated commercialisation of the bioeconomy. In response to this, an effort was undertaken with the objective of identifying key areas where standards and metrics would enable the growth of the global bioeconomy.

CEO Update - 3 June 2024

MSD Merck acquire UK biotech EyeBio for $1.3 billion upfront, ASCO and BIO conference week and the UK General election campaign produces little news for the life science sector.

CEO Update - 28 May 2024

The UK General Election has been called for Thursday, 4 July. In practical terms, this means the end of the legislative pathway for many proposals as Parliament shuts down. Keep reading for updates on our general election webinars and UK events at BIO 2024.

CEO Update - 20 May 2024

The UK continues to lead the global discussion on tackling the antibiotic emergency. Last week saw leading global figures convene at the Royal Society to pledge money and agree actions on the AMR agenda.

Spotlight on hearing therapeutics landscape: a clinical perspective

Professor Gerard O’Donoghue shares his perspective as Consultant Neurotologist at Nottingham University Hospitals NHS Trust on why he believes that the development of new treatments and their subsequent clinical adoption are vital for people living with hearing loss.

Deep Biotech companies using engineering biology for good: Epoch Biodesign case study

Featured in BIA's Deep Biotech report, Epoch Biodesign aims to revolutionize plastic waste management by creating tailor-made enzymes that efficiently depolymerize a wide range of plastics into recyclable materials, offering a circular solution to tackle plastic pollution and promote sustainability.


More within